New hires and promotions in the med-tech industry, including: Guerbet, Inquis.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abionyx, Adial, Genentech, Hansa, Lupin, Pulmatrix, Quralis, Renibus, Roche, Salarius.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Argenx, Astellas, Avrobio, Cytodyn, Iveric, Liminal, Raya, Theratechnologies.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: ADC, Alphyn, Alzheon, Bristol Myers Squibb, Celldex, Cel-Sci, Cingulate, Cognition, Daré, Enterome, Ferring, Gamida, Journey, HI-Bio, Iconovir, Inmune, Innate, Lantheus, Maia, Nacuity, Nodthera, Rakuten, Ratio, Regenxbio, Sanofi, Soligenix, Vaxcyte, Viridian.

Biopharmas raising money in public or private financings, including: Arthrosi, Evelo, Painreform, Recce, Recursion, Stuart.

New hires and promotions in the biopharma industry, including: Abivax, Aerovate, Arbutus, Azitra, Brainstorm Cell, Garuda, Neurocrine, Nymox, Ocular, Omega, Pharmajet, Syncromune, Ultragenyx.

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Argenx, Ascentage, Astellas, Astrazeneca, Ausper, Ausperbio, Drug Farm, Harbour, Iaso, Innovent, Invivyd, Kazia, Moderna, Recce, Sihuan, Skyline, Specialised, Transcenta, Xuanzhu, Zai Lab.

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Abbvie, Aimed, Alvotech, Amgen, Beigene, Biocon, Biocytogen, Boehringer Ingelheim, Celltrion, Chime, Coherus, Edirna, Fresenius Kabi, Fresenius SE, Genequantum, Hong-Kong King Friend Industry, Huadong Medicine, Innovent, Leaderna, Leads, Lipigon, Meitheal, Organon, Pheon, Remegen, Samsung Bioepis, Sandoz, Sanyou, Shionogi, Sirnaomics, SK Bioscience, Xentria, Zymedi.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Asieris, Aslan, Astellas, Astrazeneca, Biocity, Caliway, Canbridge, Daiichi Sankyo, Haemalogix, Horizon, Invivyd, Jacobio, Junshi, Microba, Nanoviricides, Neuren, Photocure, Sanofi, SK, Sorrento, Sosei, Takeda.

Biopharmas in Asia-Pacific raising money in public or private financings: Foresee, Immutep.